NAUTILUS BIOTECHNOLGY INC (NAUT)
Health Care · Proteomics Platform Development · NASDAQ
A pre-commercial proteomics platform company developing Iterative Mapping technology to enable single-molecule protein counting for comprehensive, reproducible characterization of the proteome at scale.
What NAUTILUS BIOTECHNOLGY INC does
Nautilus Biotechnology is a development-stage life sciences company focused on creating a platform technology to quantify and characterize the proteome. The company has developed Iterative Mapping, a novel analysis method that uses single-molecule counting to enable broad and deep characterization of proteins at scale. The Nautilus Voyager platform integrates nanofabricated protein arrays, affinity reagent probing, advanced optics, fluidics, and machine learning-based analysis to deliver comprehensive proteomic data. The company has not yet commercialized its platform or generated any revenue since its 2016 incorporation.
Themes: ["Proteomics platform","Single-molecule protein analysis","Biomarker discovery","Drug discovery and development","Precision medicine","Life sciences research instrumentation"]
Fundamentals
- Price$1.90 as of 2026-07-09 close
- Market cap$241M as of 2026-07-10
- 1-year return+125.3% as of 2026-07-09 close
- ROE-35.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.82 as of 2026-07-10
Key risks (from latest filing)
["The company is pre-revenue and has not yet demonstrated commercial viability; there is no assurance that research and development efforts will be successfully completed or that the Nautilus Voyager platform will be commercially viable.","The technology requires significant additional capital, personnel infrastructure, and extensive testing before commercialization; successful large-scale manufacturing of complex instrumentation and consumables with 300 unique multi-affinity reagents presents substantial technical and supply chain challenges with no guarantee of success.","The company is in early stages of establishing commercial organization and distribution capabilities; successful market adoption will depend on building reliable manufacturing partnerships, scaling production, and establishing sales infrastructure to compete in the projected $57 billion proteomics market."]
Competitors & peers
- Thermo Fisher Scientific (TMFS)
- Waters Corporation (WAT)
- PerkinElmer (PKI)
- Agilent Technologies (A)
- Bruker Corporation
- Bio-Rad Laboratories (BIO)
- Sartorius (SATYY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.